back pain; autonomic, neurological, heterogenous autoimmune disease (chronic headaches, lack of focus and comprehension); POTS (autonomic dysfunction, chronic headaches, lack of focus and comprehension, dizziness, lightheadedness, black outs, palpitations); Neurological Disorders (lack of focus and comprehension, mood swings); mast cell disease (chronic headaches); Information has been received from a lawyer, regarding a case in litigation and concerning an adolescent female patient (pt) of an unknown age. Prior to receiving the suspect vaccine, she was in her usual state of health. The pt had no autoimmune diseases, and no autonomic issues. No other information concerning the pt's medical history, concurrent conditions or concomitant medications was provided. On 23-AUG-2017, at the age of 13 years old, the pt received her first dose of quadrivalent human papillomavirus (HPV) (types 6,11,16,18) recomb. vaccine (GARDASIL) (dose, route of administration, anatomical location, lot # and expiration date were not reported) for preventing cervical cancer. On 18-NOV-2017, the pt was seen for chronic headaches that increased in frequency over the past 2 months, lack of focus and comprehension, and mood swings. On 21-NOV-2017, she was seen for dizziness, lightheadedness, headaches and black outs that had been occurring in an intermittent patterns for weeks. As the months progressed, so did the pt's injuries. She was seen by multiple physicians and specialists for her complaints which now included: headaches, dizziness, mood swings, palpitations, back pain and lightheadedness. As a result of her post-quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, the pt has been unable to engage in normal activities. As a result of pt's injuries, she was no longer able to play sports and her social life deteriorated. On unknown dates, based upon her chronic and severe post-quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, the pt was diagnosed with various medical conditions, including but not limited to postural orthostatic tachycardia syndrome (POTS), chronic headaches and mast cell disease. The pt contended that her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) injection(s) caused her to develop serious and debilitating injuries, including but not limited to autonomic, neurological, heterogenous autoimmune disease, POTS, and dysautonomia, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which were alleged herein and all of which were caused by quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) or otherwise linked to her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL)-induced autoimmune disorder. The pt had suffered and at the time of report continued to suffer severe and permanent physical injuries, and associated symptomatology and had suffered severe and permanent emotional injuries, including pain and suffering. She also had a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL). As a direct and proximate result of her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL)-induced injuries, the pt suffered and at the time of report continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and she would continue to incur these losses and expenses in the future. The outcome of the events was considered to be not recovered. The reporter considered the events to be related to quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL).  The events were considered to be disabling.  Upon internal review, the event of autoimmune disorder was determined to be medically significant.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2301USA007238: US-009507513-2301USA007261: US-009507513-2301USA007262: US-009507513-2301USA007263: US-009507513-2301USA007264: US-009507513-2301USA007265: US-009507513-2301USA007266: US-009507513-2301USA007707: US-009507513-2301USA007718: US-009507513-2301USA007723: US-009507513-2301USA007726: US-009507513-2301USA007730: US-009507513-2301USA007733: US-009507513-2301USA007734: US-009507513-2301USA007735: US-009507513-2301USA007737: US-009507513-2301USA007738: US-009507513-2301USA007740: US-009507513-2301USA007753: US-009507513-2301USA007755: US-009507513-2301USA007759: US-009507513-2301USA007760: US-009507513-2301USA007761: US-009507513-2301USA007763: US-009507513-2301USA007764: US-009507513-2301USA007766: US-009507513-2301USA007768: US-009507513-2301USA007353: US-009507513-2301USA007352: US-009507513-2301USA007351: US-009507513-2301USA007350: US-009507513-2301USA007349: US-009507513-2301USA007348: US-009507513-2301USA007347: US-009507513-2301USA007346: US-009507513-2301USA007345: US-009507513-2301USA007344: US-009507513-2301USA007343: US-009507513-2301USA007342: US-009507513-2301USA007341: US-009507513-2301USA007340: US-009507513-2301USA007339: US-009507513-2301USA007355: US-009507513-2301USA007354: US-009507513-2301USA007338: US-009507513-2301USA007498: US-009507513-2301USA007519: US-009507513-2301USA007520: US-009507513-2301USA007521: US-009507513-2301USA007522: US-009507513-2301USA007523: US-009507513-2301USA007524: US-009507513- 2301USA007593: US-009507513- 2301USA007594: US-009507513- 2301USA007595: US-009507513- 2301USA007596: US-009507513- 2301USA007597: US-009507513- 2301USA007598: US-009507513- 2301USA007599: US-009507513- 2301USA007600: US-009507513- 2301USA007601: US-009507513- 2301USA007602: